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Abstract. In contrast to TP53, cancer development is rarely 
associated with mutations in the TP63 and TP73 genes. 
Recently, next generation sequencing analysis revealed that 
TP63 mutations are frequent, specifically in cutaneous mela-
nomas. Cutaneous melanoma represents 4% of skin cancers 
but it is responsible for 80% of skin cancer related deaths. 
In the present study, we first determined whether all three 
members of the P53 family of transcription factors were found 
mutated in cutaneous melanomas by retrieving all TP53, 
TP63 and TP73 mutations from cBioPortal (http://www.
cbioportal.org/). TP53 and TP63 were frequently mutated 
[15.0% (91/605) and 14.7% (89/605), respectively], while 
TP73 [1.5% (9/605)] was more rarely mutated (p<0.0001). A 
UV-mutation fingerprint was recognized for TP63 and TP73 
genes. Then, we tried to evaluate the potential role of TP63 
mutations as drivers or passengers in the tumorigenic process. 
In the former case, the amino acid substitutions should cause 
significant functional consequences on the main biochemical 
activity of the P63 protein, namely transactivation. The 
predicted effects of specific amino acid substitutions by two 
bioinformatics tools were rather different. Using a yeast-based 
functional assay, the observed hotspot mutant R379CP63 
protein exhibited a substantial residual activity compared to 
the wild-type (>70%). This result does not support a major 
role of the mutant P63 protein in melanomagenesis while 
it is still consistent with the TP63 gene being a recorder of 
UV exposure. The TP63 mutation spectrum from cutaneous 
melanomas, when compared with that observed at the 
germinal level in patients affected by P63-associated diseases 
[ectodermal dysplasia syndromes, (EDs)], revealed signifi-
cant differences. The TP63 mutations were more frequent at 
CpGs sites (p<0.0001) in EDs and at PyPy sites (p<0.0001) 
in cutaneous melanomas. The two spectra differed signifi-
cantly (p<0.0001). We conclude that TP63 mutations are 
frequent in cutaneous melanoma, support UV etiology, but 
their role in melanomagenesis is unclear.
Introduction
The P53 family of tetrameric transcription factors is composed 
of the P53, P63 and P73 proteins (1-3) that influence many 
cellular pathways including cell proliferation, apoptosis, DNA 
repair, angiogenesis, metabolism and differentiation (4-6). 
All three proteins share an N-terminal transactivation 
domain, a central sequence-specific DNA-binding domain 
and a C-terminal oligomerization domain. Only P63 and 
P73 proteins contain an additional sterile-α-motif domain 
within the C-terminus. Moreover, the P53 family members 
can be expressed as different isoforms both at the N-terminus 
(ΔN and TA) and at the C-terminus (α-γ for P53; α-ε for P63; 
α-η for P73) through the usage of two alternative promoters 
and alternative splicing mechanisms, respectively.
Despite protein and gene structure similarities, the overlap 
in cellular functions between P53, P63 and P73 is limited as 
highlighted by comparing their role in human physiology. 
P53 is a well-known tumor suppressor protein encoded by 
one of the most frequently mutated genes in sporadic types 
of cancer. Furthermore, TP53 germline mutations are associ-
ated with the development of the cancer prone Li-Fraumeni 
and Li-Fraumeni like syndromes (7-9). Conversely, P63 is 
critical for the correct development of ectodermal-derived 
tissues, whereas P73 contributes to neural and immune system 
functions (10,11). No genetic disorder has been linked to 
TP73 germinal mutations (12), whereas heterozygous muta-
tions in the TP63 gene underlie a subset of human ectodermal 
dysplasia syndromes (EDs) (13,14).
Despite the fact that cancer development is rarely associ-
ated with TP63 and TP73 mutations, both genes play an active 
role in carcinogenesis. Flores et al (15) demonstrated the 
contribution of P63 and P73 in tumor development by revealing 
that TP63+/- and TP73+/- mice develop malignant tumors at a 
higher frequency with respect to the wild-type counterparts. 
In addition, TP53+/-TP63+/- and TP53+/-TP73+/- compound 
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mutant mice developed a more severe phenotype (e.g., more 
metastases) compared to the TP53+/- mice, indicating that P63 
and P73 have functions independent of P53.
The tumor-suppressive activities of P63 and P73 appear 
to be tissue-specific. Ιn fact, the tumor spectrum detected in 
mice defective for TP63 and TP73 is quite different from that 
of TP53-deficient mice (16). TP63+/- and TP73+/- mice develop 
primarily lung adenomas (TP63+/-, 25%; TP73+/-, 40%) squa-
mous cell hyperplasia (TP63+/-, 50%; TP73+/-, 30%), while 
TP53+/- mice primarily develop thymic lymphomas and osteo-
sarcomas. These differences are probably due to the different 
patterns of expression of the P53 family members, while P53 
is ubiquitous, the P63 and P73 proteins are highly expressed 
in epithelial tissues.
The observation that mutagens are carcinogens and that 
different mutagens induce specific spectra of mutations in genes 
frequently mutated in cancer (17), suggested that the analysis 
of the site and nature of DNA changes in genes mutated in 
tumors could be useful at identifying the factors contributing 
to the development of a specific tumor type (18,19). Molecular 
epidemiology converged to the TP53 gene, positioning it at the 
crossroad of molecular carcinogenesis and risk assessment (18). 
This was due to the fact that the TP53 gene: i) is very sensitive 
to point mutations; ii) alterations in its coding sequence occur 
in >50% of all human types of cancer; and iii) ~80% of these 
alterations are missense mutations leading to proteins with a 
single amino acid substitution (20). The relationship between 
the exposure to a carcinogen and the presence of specific TP53 
mutations in specific tumors has been extensively studied and 
described (21). TP53 mutations identified in tumors and cell 
lines have been collected in a database that contains more than 
30,000 entries (http://p53.fr/) (20).
With regard to sunlight, the International Agency for 
Research on Cancer in 1992 classified UV radiation as 
a human carcinogen (22). Upon reaching the skin, UV 
photons are absorbed by electrons of DNA, leading to the 
formation between adjacent pyrimidines of photoproducts 
known as cyclobutane pyrimidine dimers (CPDs) and 
pyrimidine 6-4 pyrimidone photoproducts (6-4PPs) (23). 
Incorrect DNA repair leads to fixation of specific C→T 
and CC→TT transitions at di-pyrimidine sites (24). About 
50% of skin cancers exhibit the signature of UV-induced 
mutagenesis on TP53 (18). TP53 mutations are frequent in 
both normal-appearing sun-exposed skin and premalignant 
actinic keratosis lesions, which are considered precursors of 
squamous cell carcinoma.
The introduction of the next generation sequencing (NGS) 
approaches on cancer cell genomes to determine the whole 
landscape of mutations in cancers, profoundly changed the 
perspective of mutational fingerprints. While the Sanger 
sequencing imposed a technical threshold (a mutation is detect-
able in a single sample if it is present in ~15-20% of the alleles), 
NGS can detect with accuracy hundreds of mutations in a single 
sample even if it is present in 1% (and even less) of the alleles.
The identification of gene mutations that directly or indi-
rectly confer a selective growth advantage to the cell in which 
they occur (‘driver mutations’) among a plethora of other 
mutations devoid of a role in the cancer process (‘passenger 
mutations’) is a formidable challenge. The situation is even 
more complicated, since a driver gene (i.e., that can harbor 
driver mutations) may also contain passenger mutations. A 
review suggests that, considering all types of tumors, the total 
number of driver genes in cancer which was discovered through 
the NGS approach is ~125, 29% of which was discovered 
through the NGS approach (25). Numerous statistical methods 
have been described to distinguish between driver versus 
passenger mutations (26-28). Furthermore, the number of 
driver mutations sufficient for a cell to evolve into an advanced 
cancer is thought to be extremely low. Ιn solid tumors of adults, 
including melanoma, alterations in as few as three driver 
genes are sufficient (29,30). This pointed towards the idea that 
pathways, rather than individual genes, appear to govern the 
tumorigenic process (25), which has rendered complex cancer-
genome landscapes intelligible and exploitable.
Cutaneous melanoma represents 4% of skin cancers but 
is responsible for 80% of skin cancer related deaths, corre-
sponding to ~1-2% of all cancer related deaths (31). Cutaneous 
melanoma, which develops from epidermal melanocytes of the 
skin, represents the most common melanoma. Sun exposure 
is accepted as a major causative factor of melanomas (32). 
Cutaneous melanomas have been studied by NGS since 
2010 (33). This analysis generated the first comprehensive 
catalogue of somatic mutations from a malignant melanoma, 
revealing that the predominant mutational signature reflects 
DNA damage due to UV exposure. Moreover, through analysis 
of large-scale melanoma exome data, hodis et al (34) discov-
ered six novel driver melanoma genes (PPP6C, RAC1, SNX31, 
TACC1, STK19 and ARID2), providing unequivocal genomic 
evidence for a direct mutagenic role of UV light in melanoma 
pathogenesis. Recently, the sequence of genetic alterations 
during melanoma progression was defined, revealing distinct 
evolutionary paths for different melanoma subtypes (35,36). 
While benign lesions harbored BRAF V600E mutations 
exclusively, those classified as ‘intermediate’ were enriched 
for NRAS mutations and additional driver mutations. 
TERT promoter mutations were observed at a high incidence 
in intermediate lesions and melanomas in situ. Biallelic 
CDKN2A inactivation emerged exclusively in invasive mela-
nomas, while PTEN and TP53 mutations were found only in 
advanced primary melanomas and their presence appears to 
represent the transition to metastatic tumors (36).
Recently, using NGS, missense mutations in the TP63 gene 
were frequently and specifically found in cutaneous mela-
nomas (~15%) (37). This observation prompted us to study the 
features of TP63 mutations from the molecular epidemiology 
point of view and to ascertain whether all three members of the 
P53 family were mutated in melanomas with equal frequency.
Materials and methods
Data collection. A total of 605 cases were considered by 
reviewing all studies documenting TP53/TP63/TP73 mutations 
in cutaneous melanomas retrieved from cBioPortal (http://
www.cbioportal.org) (38,39). Eighty nine of them exhibited 
a total of 111 TP63 mutations, 91 cases exhibited a total of 
105 TP53 mutations and only 9 cases exhibited a total of 
10 TP73 mutations (40,41).
TP63 mutations associated to EDs were retrieved from 
literature reporting amino acid substitutions and the caus-
ative single base pair substitution deduced from the genetic 
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code (13,42,43). Excluding a tandem mutation (CGC>CAA, 
R318Q), a total of 101 TP63 base pair substitutions found in 
EDs were considered.
In order to infer the potential role of the different muta-
tions in terms of driver or passenger mutations, the output 
of two bioinformatic predictors, namely mutation assessor 
and functional analysis through hidden Markov models, 
FAThMM-MKL (an algorithm which predicts the functional, 
molecular and phenotypic consequences of protein missense 
variants using hidden Markov models, and classifies as ‘patho-
genic’ or ‘neutral’ mutations if the scores are ≥0.7 or ≤0.5, 
respectively) were retrieved from cBioPortal.
Statistical analysis. In order to rigorously compare mutational 
spectra observed at the same locus, i.e., considering where 
along the nucleotide sequence the mutation was observed, 
and how many independent mutations were observed in each 
specific position, the Adams and Skopek algorithm (44) and 
the program from Cariello et al were used (45).
The Adams and Skopek algorithm uses a Monte Carlo 
method to simulate a P-value of the standard hypergeometric 
test for a contingency table (44). Unlike the χ2 test, which can 
also be applied to contingency tables and requires that all 
cells contain five or more events, the hypergeometric test is 
appropriate when applied to sparse data sets, often found in 
mutational spectra analyses. The Cariello et al program (45) 
uses a random number generator to produce a large number 
of simulated spectra based on the hypergeometric probability 
of the experimentally observed input spectra. The degree to 
which the simulated spectra differ from the input spectra is 
used to estimate the probability that the two input spectra were 
derived from the same population. A P-value <0.05 leads to 
the rejection of the null hypothesis and to the conclusion that 
the input spectra are different.
Yeast strains and media. The issue of P53 family transacti-
vation specificity was thoroughly investigated by our group 
taking advantage of the previously described yeast functional 
assay (luciferase reporter-based assay) (8,9,20,46). In partic-
ular, in order to evaluate the functionality of the P63 R379C 
allele, it was cloned into a yeast expression vector as ΔN-P63α 
and TA-P63α isoforms; their functionality was evaluated 
in two yeast reporter strains containing the luciferase gene 
under the control of the P63 responsive genes P21 and PERP. 
yLFM-P21-5' and yLFM-PERP yeast strains were used (14); 
the two strains are isogenic except for the different Response 
Element (RE) (20 bp) located upstream the luciferase reporter 
gene. Cells were grown in YPDA medium (1% yeast extract, 
2% peptone, 2% dextrose, 200 mg/l adenine) or in a selective 
medium containing dextrose or raffinose as a carbon source 
and adenine (200 mg/l) but lacking tryptophan (Sigma-
Aldrich, St. Louis, MO, USA; BiokarDiagnostics, Pantin, 
France). Galactose was added to the medium to modulate P63 
expression under the inducible GAL1-GAL10 promoter.
Yeast vectors. pTSG-based vectors expressing wild-type 
ΔN-P63α and TA-P63α isoforms were already available (14). 
Yeast vectors expressing mutant isoforms (ΔN-P63α R379C 
and TA-P63α R379C) were constructed using the experimental 
strategy as previously described (9,14). Briefly, for R379C 
mutation, a pair of complementary oligonucleotides (which 
served as forward and reverse primers) was synthesized, with 
the mutated nucleotide (underlined the corresponding codon) 
adjacent to the central position (R379C forward, 5'-aagcgcccgt 
tttgtcagaacacacatggt-3' and reverse, 5'-accatgtgtgttctgacaaaac-
gggcgctt-3'). Forward and reverse primers, paired respectively 
with α-Cter and ΔN-Nter (or TA-Nter) primers (ΔN-Nter, 
5'-caagctataccaagcatacaatcaactatctcatatacagttaactcgagatgttgta 
cctggaaaacaat-3'; TA-Nter, 5'-caagctataccaagcatacaatcaac-
tatctcatatacagttaactcgagatgtcccagagcacacagaca-3'), were used 
in two separate PCR reactions with the pcDNA3.1 TP63α 
plasmid (ΔN or TA isoform) as template. The following PCR 
conditions were used: 1 min of denaturation at 94̊C, 1 min of 
annealing at 55̊C and 2 min of elongation at 72̊C (35 cycles) 
(Exact polymerase, 5 prime). Unpurified aliquots of PCR 
products were then transformed in yIG397 yeast strain together 
with an XhoI/NotI (New England Biolabs, Ipswich, MA, USA) 
digested pTS-based vector. In yeast, the plasmid is re-sealed 
together with the PCR products by recombination, exploiting 
the sequence homology at the end of the fragments (gap repair 
assay) (8,9). Plasmid DNA was recovered from yeast colonies, 
expanded in E. coli, and checked by digestion; the presence of 
the specific mutation was verified by DNA sequencing (BMR 
Genomics, Padova, Italy).
Yeast vectors expressing R379C mutant protein (ΔN-P63α 
and TA-P63α isoforms) under the inducible GAL1-GAL10 
promoter (pTSG-based), were constructed by double-digesting 
the pTS-based expression vectors with the XhoI and NotI 
restriction enzymes. The DNA fragment containing the 
mutant ΔN- or the TA-TP63α coding sequence (cDNA) was 
then cloned in a double-digested pTSG-based vector (14).
Yeast functional assay. P63 wild-type and mutant isoforms 
(ΔN-P63α and TA-P63α) were expressed by a pTSG-based 
vector (TRP1 selection marker) (14). Plasmid pRS314 (TRP1) 
was used as an empty vector. The functional assay was 
conducted according to the miniaturized protocol we devel-
oped (14,46). Briefly, yeast strains were transformed (LiAc 
method) with the pTSG-based expression vectors along with 
the empty vector. Yeast transformants were resuspended in 
minimal synthetic medium containing raffinose plus galac-
tose (0,128%) in a final volume of 200 µl (96-well plates) 
and were grown for 8 h with vigorous shaking at 30̊C. The 
OD (600 nm) was then directly assessed in the transparent 
96-well plate. Twenty microliters of cell suspension were trans-
ferred in a white plate and mixed with an equal volume of 
PLB buffer 2X (Passive Lysis Buffer; Promega, Madison, WI, 
USA) in order to obtain the lysis of yeast cells. After 15 min 
of shaking at room temperature, 20 µl of Firefly luciferase 
substrate (Bright Glo; Promega) were added. The luciferase 
activity was assessed using a multilabel plate reader (Mithras 
LB 940; Berthold Technologies, Bad Wildbad, Germany) 
and normalized to OD 600 nm. The transactivation ability of 
the wild-type and mutant P63 proteins was expressed as fold 
of induction over empty vector for each reporter strain; the 
percentage of the luciferase activity of the P63 mutants with 
respect to the wild-type was also calculated.
Western blot analysis. Yeast transformants in the yLFM-P21-5' 
and yLFM-PERP strains were grown 8 h in selective medium 
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containing 0.128% galactose and collected by centrifugation. 
Cells were resuspended in 100 µl distilled water, and 100 µl 
0.2 M NaOh were then added. The mixture was then incubated 
for 5 min at room temperature, pelleted, resuspended in 50 µl 
SDS sample buffer (0.06 M Tris-hCl, ph 6.8, 5% glycerol, 
2% SDS, 4% β-mercaptoethanol, 0.0025% bromophenol blue), 
boiled for 3 min and pelleted again (47). Ten microliters of 
yeast supernatant were resolved on 4-15% Mini-Protean TGX 
gels and transferred to nitrocellulose membranes by Trans-Blot 
Turbo Blotting System using the Trans-Blot Transfer Pack, 
(Bio-Rad, Hercules, CA, USA). A specific antibody directed 
against P63 (clone 4A4, sc-8431; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) was diluted in 1% non-fat dry milk 
dissolved in PBS-T. Phosphoglycerate kinase 1 (PGK1) was 
used as a loading control (clone 22C5D8; Life Technologies; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA). After 
washing, the blots were incubated with the appropriate IgG 
horseradish peroxidase-conjugated secondary antibody (anti-
mouse IgG hRP, A9044; Sigma-Aldrich, St. Louis, MO, USA), 
and immune complexes were visualized with ECL Fast Pico 
(Immunological Sciences, Rome, Italy). Chemiluminescence 
was analyzed by Alliance LD (Uvitec, Cambridge, UK).
Results
TP53 and TP63, but not TP73, are frequently mutated 
in cutaneous melanomas. All TP53, TP63 and TP73 
mutations in cutaneous melanomas were retrieved from the 
cBioPortal (http://www.cbioportal.org) (38,39). Overall, the 
incidence of TP53 and TP63 mutations was similar [15.0% 
(91/605) and 14.7% (89/605) for TP53 and TP63, respectively] 
while the frequency of TP73 mutations [1.5% (9/605)] was 
significantly lower (p<0.0001). Since some melanomas 
exhibited more than a single mutation, a total of 105 TP53, 
111 TP63 and 10 TP73 mutations were retrieved and their 
molecular features analyzed (Table I). Clearly, for all three 
genes the majority (>83%) of mutations were single base 
pair substitutions (TP53, 88/105=83.8%; TP63, 101/111=91%; 
TP73, 10/10=100%), at least 80% of which were localized at 
adjacent pyrimidines (PyPy). At least 50% of all base pairs 
substitutions for all three genes were GC>AT transitions. Their 
codon localization along each cDNA sequence is represented 
in Fig. 1.
Thus, TP53 and TP63, but not TP73, mutations are 
frequently found in cutaneous melanomas and their molecular 
features are reminiscent of a UV-exposure, suggesting 
that TP53 and TP63 genes behave like two ‘recorders of 
UV-exposure’. This conclusion is indirectly supported by the 
fact that among 80 patients with uveal melanomas, a form of 
melanoma that should be less UV-dependent since the UV 
radiation should not have the power to hit the target tissue, 
none of them displayed TP53 and TP63 mutations (TCGA 
study) (http://www.cbioportal.org).
The TP63 mutation fingerprint in cutaneous melanomas is 
distinguishable from the one observed in P63-associated 
EDs. To verify the assumption of molecular epidemiology, 
namely that carcinogens leave distinguishable fingerprints, 
101 germinal TP63 mutations found in patients affected 
by a specific subset of EDs were retrieved from the 
literature (13,42,43). Excluding a tandem mutation 
(1 CGC>CAA, R318Q) with no feature of UV-induced 
Table I. Comparison of TP53, TP63 and TP73 mutations in cutaneous melanomas (n=605).
Types of mutations TP53 TP63 TP73
No. of cases with mutations 91 89 9
No. of cases with mutations/total (%) 91/605 (15.0)a 89/605 (14.7)b 9/605 (1.5)a,b
No. of mutations 105 111 10
Type of mutations
  Frameshift Del/Ins 8 1 0
  Tandem mutations 2 1 0
  Splice mutations 7 8 0
  Single bp 88 101 10
    Classes of bp, n (%)
    AT>CG 5 (6) 0 (0) 1 (10)
    AT>GC 6 (7) 4 (4) 1 (10)
    AT>TA 5 (6) 3 (3) 1 (10)
    GC>AT 65 (73) 92 (91) 5 (50)
    GC>CG 5 (6) 1 (1) 2 (20)
    GC>TA 2 (2)  1 (1) 0 (0)
Localization at CpGs, n/total (%) 23/88 (26) 37/101 (37) 1/10 (10)
Localization at PyPy, n/total (%) 75/88 (85) 98/101 (97) 8/10 (80)
Data from cBioPortal for Cancer Genomics for cutaneous melanomas. ap<0.0001, bp<0.0001. PyPy, pyrimidines.
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tandem mutation, a total of 100 TP63 base pair substitutions 
were analyzed and compared with the TP63 mutations found 
in cutaneous melanomas (Table II). The genesis of the former 
mutations is most likely unrelated to UV-exposure. If the 
classes of mutations were considered, the only significant 
difference between the two spectra is a higher percentage 
of GC>AT transitions in melanomas than in EDs (92/101; 
91% vs. 76/101; 76%; p<0.0005). However, significant and 
interesting differences emerged when the localization of 
mutations at CpGs or PyPy sites was considered. Indeed, 
significantly more TP63 mutations were located at CpGs 
in EDs than in melanomas (74 vs. 37%; p<0.0001), and 
vice versa, significantly more TP63 mutations were 
located at PyPy in melanomas than in EDs (97 vs. 70%; 
p<0.0001). Finally, the two TP63 mutation spectra appeared 
significantly different (p<0.0001; Fig. 2) also when the 
sequence distribution of independent base pair substitutions 
along the TP63 nucleotide sequence was compared using 
the Cariello et al program (45), which provides a rigorous 
statistical test of the relatedness of two spectra at the same 
locus.
In conclusion, using a mutational spectrometry approach 
we demonstrated that a UV fingerprint could be recognized 
in the TP63 mutations found in cutaneous melanomas and 
that such a mutation spectrum is distinguishable from the one 
observed in EDs.
TP53 and TP63 mutations in cutaneous melanomas: drivers, 
or passengers? A tentative answer from bioinformatics 
prediction of the functional consequences of TP53 and TP63 
mutations. Since TP53 and TP63 mutations are relatively 
frequent in cutaneous melanomas a question arises. Do these 
mutations play a role as potential drivers or passengers in the 
tumorigenic process? To answer this question, for each muta-
tion we first registered the classifications (Mutation Assessor 
and FAThMM-MKL) reported at the cBioPortal (http://www.
cbioportal.org) (41,42). To act as a driver, the mutations should 
have consequences on the functionality of the P53/P63 proteins 
(i.e., amino acid substitution should cause a change in transac-
tivation capacity of the mutant with respect to the wild-type 
protein). When the functional consequences of mutations were 
evaluated using the Mutation Assessor bioinformatics tool a 
significantly larger proportion of TP53 mutations (TP53: 60/64, 
93.7%; TP63: 32/95, 33.7%; p<0.0001, Fisher's exact test) were 
classified to have a medium impact on protein functionality, 
while a significantly larger proportion of TP63 mutations 
(TP63: 42/95, 44.2%; TP53: 2/64, 3.1%; p<0.0001 Fisher's 
exact test), were classified to have a neutral impact on protein 
functionality (Table III). When prediction was performed with 
the FAThMM-MKL bioinformatics tool each and every single 
amino acid substitution in TP63 was predicted to be patho-
genic (score>0.89) (Table III). Furthermore, no significant 
difference emerged among specific mutations since almost 
Figure 1. Sequence distribution along the TP53, TP63 and TP73 nucleotide 
positions of independent single base pair substitutions in cutaneous mela-
nomas retrieved from cBioPortal (http://www.cbioportal.org).
Figure 2. Distribution of TP63 single base pair substitutions found in 
cutaneous melanomas (n=101) and at the germinal level in patients affected 
by P63-associated diseases (EDs). The two mutation spectra compared 
using the Cariello et al program (45) differed significantly (p<0,0001). EDs, 
ectodermal dysplasia syndromes.
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all TP53 and TP63 mutations were classified as pathogenic. 
Therefore, independent bioinformatics tools reveal a role of 
TP53 as a driver gene in cutaneous melanomas, while for TP63 
mutations the situation is less clear. however, the abundance 
of TP63 mutations (similar to the one of TP53) along with the 
FAThMM-MKL prediction reveal that TP63 mutations may 
play some role in cutaneous melanomas.
From bioinformatics prediction to experimental determina-
tion of P63 functionality: the P63 R379C hotspot mutant 
protein in melanomas retains residual wild-type function. 
In order to shed more light on the functional effects of 
amino acid substitutions, we experimentally determined 
the outcome of the substitution of the arginine at codon 379 
with a cysteine (R379C) on the transactivation ability of 
the P63 protein. This mutant protein represents the most 
frequent amino acid substitution observed in cutaneous 
melanomas (mutation hotspot). Furthermore, while Mutation 
Assessor predicts that this amino acid substitution will have 
a low impact on functionality, conversely FAThMM predicts 
it as pathogenic. For this purpose the P63 R379C allele 
was cloned into a yeast expression vector as ΔN-P63α and 
TA-P63α isoforms, and their functionality was evaluated in 
two yeast reporter strains containing the luciferase gene under 
the control of the P63 responsive genes P21 and PERP (see 
materials and methods for details).
The results revealed that the R379C amino acid substitution 
did not markedly affect the transactivation ability of ΔN-P63α 
and TA-P63α proteins with respect to the wild-type (Fig. 3A). 
Specifically, when expressed as the ΔN-P63α isoform the 
R379C protein exhibited a transactivation activity comparable 
to that of the wild-type P63. When expressed as the TA-P63α 
isoform, the same amino acid substitution exhibited, in both 
yeast strains, a decrease of transactivation ability of ~30% with 
respect to the wild-type. Such a difference in transactivation 
Table III. Functional evaluation of amino acid substitutions 
using bioinformatics tools.
    TP53 vs. TP63
Type of mutations TP53 TP63 TP73 (P-value)
No. of mutations 105 111 10





  Mutation Assessor 64 95 9
    Neutral 2 42 6 <0.0001
    Low 2 21 1 <0.009
    Medium 60 32 2 <0.0001
    high 0 0 0
  FAThMM prediction 88 79 7
    Neutral 2 0 3 NS
    Pathogenic 86 79 4 NS
Since the numerosity of the TP73 group is one order of magnitude 
lower than those of the TP63 and TP53 samples, only statistical com-
parisons performed between the TP53 vs. TP63 group of samples are 
reported. NS, not significant.
Table II. Comparison of TP63 mutations in cutaneous melanomas and in a subset of human EDs.
   Melanoma vs. EDs
Type of mutations Melanomasa EDsb (P-value)
No. of mutations 111 101
Type of mutations
  Frameshift Del/Ins 1 0
  Tandem mutations 1 1
  Splice mutations 8 0
  Single bp substitutions 101 100
    Classes of bp substitutions, n (%)
    AT>CG 0 (0) 4 (4) NS
    AT>GC 4 (4) 9 (9) NS
    AT>TA 3 (3) 3 (3) NS
    GC>AT 92 (91) 76 (76) <0.0005
    GC>CG 1 (1) 3 (3) NS
    GC>TA 1 (1) 5 (5) NS
Localization at CpGs, n/total (%) 37/101 (37) 74/100 (74) <0.0001
Localization at PyPy, n/total (%) 98/101 (97) 70/100 (70) <0.0001
aData From cBioPortal for Cancer Genomics for cutaneous melanomas; breconstruction of 101 base pair substitutions found in EDs according 
to literature. EDs, ectodermal dysplasia syndromes; PyPy, pyrimidines; NS, not significant.
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ability cannot be due to a lower amount of mutant TA-P63α 
protein compared to the wild-type counterpart, since both 
proteins were equally expressed (Fig. 3B). These results suggest 
that, according to our yeast-based P63 functional assay (14), 
the R379C mutant P63 cannot be immediately classified as a 
potential pathogenic. In this line it is worth noting that this 
amino acid is not evolutionarily conserved within P53 family 
members, suggesting the lack of a key role in the P63 protein 
functionality; consequently, it is possible to hypothesize that 
amino acidic substitutions at this position can be well tolerated 
without markedly altering the transactivation ability of the 
protein.
Discussion
NGS approaches of cancer genomes introduce a new scenario 
also for cutaneous melanomas. Cutaneous melanomas were 
submitted to NGS for the first time in 2010 (33). Two years 
later, hodis et al (34) discovered novel melanoma genes and 
revealed that the spectrum of mutations provided evidence 
for a direct mutagenic role of UV light in melanomagenesis. 
More recently, a distinct sequence of genetic alterations during 
melanoma progression for different melanoma subtypes was 
defined (35,36). Benign lesions exclusively harbored BRAF 
V600E mutation, whereas those categorized as ‘intermediate’ 
were enriched for NRAS mutations and additional driver muta-
tions. Biallelic CDKN2A inactivation emerged exclusively in 
invasive melanomas, while the presence of PTEN and TP53 
mutations appears to represent the transition to metastatic 
tumors (36).
Only recently missense mutations in the TP63 gene were 
noted to be frequently and specifically found in cutaneous 
melanoma (~15%) (37) in contrast to the previous prevailing 
notion that TP63 mutations are seldom found in cancer. 
This observation prompted us to ascertain whether all three 
members of the P53 family of transcription factors were found 
mutated in cutaneous melanomas (http://www.cbioportal.
org) (38,39). Notably, TP53 and TP63 were frequently mutated 
in cutaneous melanomas (15.0 and 14.7%, respectively) while 
the incidence of TP73 mutations (1.5%) was significantly 
lower (p<0.0001).
The TP63 and TP53 mutations found in cutaneous mela-
nomas revealed a UV-recognizable mutation fingerprint, 
high percentage of GC>AT transitions at PyPy sites, along 
with a few tandem mutations (Table I). These observations 
strongly suggest that TP63 and TP53 mutations in cutaneous 
melanomas are UV-induced. To reinforce this suggestion 
the TP63 mutations found in cutaneous melanomas were 
compared with those observed at the germinal level in patients 
affected by a specific subset of P63-associated disorders (EDs). 
Since the two sets of mutations should have been induced by 
different mutagenic events, based on the mutation spectrom-
etry assumption, we anticipated that the two TP63 mutation 
spectra would be distinguishable. Indeed, they were signifi-
cantly different. The TP63 mutations in EDs were significantly 
more frequent at CpGs sites (p<0.0001; Table II), while those 
in skin melanomas were significantly more frequent at PyPy 
sites (p<0.0001; Table II). Furthermore, the sequence distri-
bution of independent TP63 base pair substitutions along the 
nucleotide sequence differed significantly in the two spectra 
(p<0.0001; Fig. 2). Altogether these results demonstrated that 
the TP63 mutations observed in cutaneous melanomas are 
UV-specific, while those observed in EDs are likely of sponta-
neous origin, with deamination of 5'-mC at CpG sites being a 
likely candidate responsible of such events.
Altogether these results suggest that, besides TP53, 
TP63 mutations, but not TP73, may also play a role in 
melanomagenesis. however, if this is so, it is expected 
that the corresponding amino acid substitutions induced 
by those mutations would show significant functional 
consequences on the transcriptional activity of the P63 
protein. The predictions based on two bioinformatics tools 
(Mutation Assessor and FAThMM) were rather different. 
Figure 3. (A) Functional characterization of the mutant R379C P63 protein 
using the yeast-based transactivation assay. ΔN-P63α or TA-P63α isoforms 
of the wt or mutant R379C P63 protein were expressed under the GAL1-10 
inducible promoter (8 h at 0.128% galactose) in two isogenic yeast reporter 
strains (yLFM-P21-5'; yLFM-PERP) having the luciferase reporter gene 
under the control of P53 responsive element present in the promoter region 
of the P21 and the PERP gene. Presented in the graph is the fold-induction 
over the empty expression vector (pRS314) of mean luciferase activities nor-
malized to optical density (OD) at 600 nm. Average and standard errors of 
three biological replicates are plotted. (B) Western blot analysis of different 
isoforms (TA and ΔN) of P63α proteins revealed that wt and R379C are 
expressed at similar level in yeast cells. A specific antibody directed against 
P63 was used to quantify the P63 isoforms. PGK1 was used as a loading con-
trol. The P63/PGK1 ratio is similar within a specific situation (e.g., strain and 
isoform) for the wt and R379C protein. PGK1, phosphoglycerate kinase 1.
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While the former discriminated between the effects 
of specific amino acid substitutions on the P63 protein 
functionality, the latter predicted that all the mutations 
were pathogenic (Table III). Therefore, we experimentally 
determined the functional consequences of the TP63 R379C 
mutation on the transactivation ability with respect to the 
wild-type counterpart, since this mutant P63 protein was the 
most frequent amino acid substitution observed in cutaneous 
melanomas and the two bioinformatics tools reported different 
prediction for the same mutation. Using our yeast-based P63 
functional assay the R379C protein exhibited a substantial 
residual activity compared to the wild-type (70-100%, 
depending on the yeast reporter strain) (Fig. 3). This result 
is in keeping with the prediction of the Mutation Assessor 
and appears to not support a major role of this mutant P63 
protein in melanomagenesis, while it is still compatible with 
the TP63 gene being a recorder of UV exposure. With regard 
to the TP53 hot spot mutation in melanomas, i.e., R213Stop, it 
is obligatorily classified as a loss-of-function mutant because 
the mutation results in a truncated P53 protein that is not 
able to oligomerize. This observation is in agreement with 
the predictions of the bioinformatics tools suggesting that 
TP53 mutations may play a role in melanomagenesis.
While TP53 mutations have been recognized to play a 
role in the transition to metastatic tumors (36), the indica-
tions for the role of TP63 mutations have yet to be elucidated. 
The fact that TP63+/- mice developed malignant tumors at a 
higher frequency with respect to the wild-type counterpart, 
and that the TP53+/-TP63+/- compound mutant mice devel-
oped a more severe phenotype (i.e., higher tumor burden and 
more metastases) compared to the TP53+/- mice, reveals that 
TP63 is a tumor/metastasis suppressor gene independent of 
P53 (15). Thus, TP63 mutations that inactivate the protein 
function likely contribute to a carcinogenic process. however, 
besides their relative frequency, TP63 mutations in cutaneous 
melanomas possibly represent a record of exposure (passenger 
mutations) rather than driver mutations. This conclusion 
is supported by additional arguments. Firstly, through an 
extensive study that considers all type of tumors (48) TP53 
is present among the 125 drivers genes recognized, while 
TP63 is not. Secondly, TP63 and TP53 mutations have a 
significant tendency towards co-occurrence (p<0.001) (http://
www.cbioportal.org) in melanomas, a situation that does not 
support the hypothesis that both mutations may play a major 
role during melanomagenesis. Thirdly, a possible mechanism 
through which the mutant P53 protein may facilitate the 
transition towards metastatic melanomas may be via interfer-
ence with the antimetastatic function of the wild-type P63. 
Adorno et al (49) proposed such a mechanism in breast cancer 
cells, revealing that TGF-β-dependent cell migration, invasion 
and metastasis were empowered by the mutant P53 protein and 
opposed by P63: a mutant P53/P63 protein complex appeared 
assembled with SMAD proteins which served as an essential 
platform. Notably, the TGF-β/SMAD pathway appears to be 
active even in melanomas (50). Thus, the mere presence of a 
mutant P53 protein may be sufficient to antagonize the P63 
function without the need to mutate TP63.
It should also be considered that TP53/TP63 mutations 
may also play different roles according to the phase of cancer 
development in which they occur. UV-induced TP53/TP63 
mutations at PyPy sites are an early event in UV-exposed skin 
that it is still devoid of any cancer-like phenotype. however, 
the presence of these mutations with their effects may allow 
mutated cells to escape apoptosis, thus progressing towards 
more advanced stages of the carcinogenesis process. In this 
view, TP53/TP63 may be considered driver mutations of 
the early carcinogenesis steps. In more advanced cancer 
stages or in full blown cancer the burden of other mutations 
prevails, thus giving cancer an aggressive behavior resulting 
in chemoresistance, metastatisation and decreased survival. 
Accordingly, TP53/TP63 behave as passenger mutations in 
these advanced cancer stages.
Two other aspects contribute to maintain the role of TP63 
mutations in cutaneous melanomas uncertain. The first is 
related to a recent study by Matin et al (51) who demonstrated 
that the two wild-type isoforms of P63, namely TA-P63 and 
ΔN-P63, play an anti-apoptotic role in melanoma and confer 
chemoresistance, even in the absence of TP53 mutations. 
In response to DNA damage, P63 is stabilized in the nuclei 
and translocates to the mitochondria where it supresses 
apoptosis through a direct and indirect inhibitory function on 
P53-dependent pro-apoptotic effectors. In this scenario, the 
selection of TP63 mutations during melanomagenesis appears 
to be unnecessary or even deleterious for tumor growth, once 
again pointing toward a passenger role rather than a driver 
role for such mutations. Moreover, this observation highlights 
functions of the P63 protein that are not associated to the 
key role as nuclear transcription factor. The second aspect is 
related to the power of the NGS; in fact, while the Sanger 
sequencing imposed a technical threshold of detection (i.e., a 
mutation could be identified if present in ~20% of the alleles), 
NGS can accurately detect mutations at an abundance in the 
order of 1% (and even lower). The presence of every mutation 
identified with NGS facilitate the identification of mutational 
signatures. however, the biological impact of a mutation that 
is 1 or 20% abundant may be different on tumor behavior. In 
view of understanding which mutations are really important 
for the carcinogenic process, an interesting way would be to 
submit to NGS consecutive samples, spaced in time, and to 
verify what happens to the abundance of specific molecular 
events in the progression of the tumor. This is relatively 
easy for some hematological malignancies (e.g., chronic 
lymphocytic leukemia, CLL); however this appears to be very 
difficult, or even impossible, for others kind of tumors. In 
CLL, Rossi et al (52) revealed that TP53 mutations, even in 
<1% of the CLL clone, can be selected upon treatment and 
therefore should be taken into account when defining therapy 
protocols.
We conclude that TP63 mutations are frequent in cutaneous 
melanoma and support UV etiology, however they do not have 
a clear role in melanomagenesis. The role of TP63 mutations 
changes according to the stage of melanoma carcinogenesis 
when they occur being drivers in early stages and passengers 
in late stages. In the absence of experimental results on gene 
mutation functionality, bioinformatics tools are often used to 
predict the effect of a single amino acid substitution on the 
function of the protein under study. Our results clearly revealed 
that the experimental data obtained with our yeast-based func-
tional assay may be useful to elucidate the role of mutations on 
P63 function.
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